Molecular Biology Reports

, Volume 39, Issue 2, pp 2039–2044 | Cite as

CXCL12 G801A polymorphism and breast cancer risk: a meta-analysis

Article

Abstract

The G801A polymorphism in the CXCL12 gene has been implicated in breast cancer risk. However, the published findings are inconsistent. We therefore performed a meta-analysis to investigate this relationship. Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the association. The pooled ORs were performed for codominant model, dominant model, and recessive model, respectively. Five published case–control studies, including 1,058 breast cancer cases and 1,023 controls were identified. No study had a deviation from the Hardy–Weinberg equilibrium (HWE) in controls. We found that the CXCL12 G801A (rs1801157) polymorphism was associated with a significantly increased risk of breast cancer risk when all studies were pooled into the meta-analysis (codomiant model: AA versus GG, OR = 1.64, 95% CI = 1.16–2.33; GA versus GG, OR = 1.42, 95% CI = 1.18–1.71; dominant model: AA/GA versus GG, OR = 1.44, 95% CI = 1.21–1.72). Furthermore, Egger’s test did not show any evidence of publication bias (P > 0.05 for the dominant model). In conclusion, the results suggest that the CXCL12 G801A polymorphism may be a low-penetrant risk factor for developing breast cancer.

Keywords

CXCL12 Breast cancer Meta-analysis Molecular epidemiology 

Notes

Acknowledgments

The authors are fully responsible for all content and editorial decisions and did not receive financial support or other form of compensation related to the development of the manuscript.

Conflicts of interest

The authors declare no any conflicts of interest in this work.

References

  1. 1.
    Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56:168–183PubMedCrossRefGoogle Scholar
  2. 2.
    Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000) Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343:78–85PubMedCrossRefGoogle Scholar
  3. 3.
    Zlotnik A, Yoshie O (2000) Chemokines: a new classification system and their role in immunity. Immunity 12:121–127PubMedCrossRefGoogle Scholar
  4. 4.
    Caux C, Ait-Yahia S, Chemin K, de Bouteiller O, Dieu-Nosjean MC, Homey B, Massacrier C, Vanbervliet B, Zlotnik A, Vicari A (2000) Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol 22:345–369PubMedCrossRefGoogle Scholar
  5. 5.
    Rossi D, Zlotnik A (2000) The biology of chemokines and their receptors. Annu Rev Immunol 18:217–242PubMedCrossRefGoogle Scholar
  6. 6.
    Balkwill F (2003) Chemokine biology in cancer. Semin Immunol 15:49–55PubMedCrossRefGoogle Scholar
  7. 7.
    Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR (1998) Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393:595–599PubMedCrossRefGoogle Scholar
  8. 8.
    Olson KE, Booth GC, Poulin F, Sonenberg N, Beretta L (2009) Impaired myelopoiesis in mice lacking the repressors of translation initiation, 4E-BP1 and 4E-BP2. Immunology 128:e376–e384PubMedCrossRefGoogle Scholar
  9. 9.
    Ben-Baruch A (2003) Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 5:31–36PubMedCrossRefGoogle Scholar
  10. 10.
    Kato M, Kitayama J, Kazama S, Nagawa H (2003) Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma. Breast Cancer Res 5:R144–R150PubMedCrossRefGoogle Scholar
  11. 11.
    Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M, Dean M, Honjo T, Tashiro K, Yabe D et al (1998) Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 279:389–393PubMedCrossRefGoogle Scholar
  12. 12.
    Watanabe MA, de Oliveira Cavassin GG, Orellana MD, Milanezi CM, Voltarelli JC, Kashima S, Covas DT (2003) SDF-1 gene polymorphisms and syncytia induction in Brazilian HIV-1 infected individuals. Microb Pathog 35:31–34PubMedCrossRefGoogle Scholar
  13. 13.
    Handoll HH (2006) Systematic reviews on rehabilitation interventions. Arch Phys Med Rehabil 87:875PubMedCrossRefGoogle Scholar
  14. 14.
    Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719–748PubMedGoogle Scholar
  15. 15.
    DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188PubMedCrossRefGoogle Scholar
  16. 16.
    Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629–634PubMedCrossRefGoogle Scholar
  17. 17.
    Zafiropoulos A, Crikas N, Passam AM, Spandidos DA (2004) Significant involvement of CCR2–64I and CXCL12–3a in the development of sporadic breast cancer. J Med Genet 41:e59PubMedCrossRefGoogle Scholar
  18. 18.
    Razmkhah M, Talei AR, Doroudchi M, Khalili-Azad T, Ghaderi A (2005) Stromal cell-derived factor-1 (SDF-1) alleles and susceptibility to breast carcinoma. Cancer Lett 225:261–266PubMedCrossRefGoogle Scholar
  19. 19.
    de Oliveira KB, Oda JM, Voltarelli JC, Nasser TF, Ono MA, Fujita TC, Matsuo T, Watanabe MA (2009) CXCL12 rs1801157 polymorphism in patients with breast cancer, Hodgkin’s lymphoma, and non-Hodgkin’s lymphoma. J Clin Lab Anal 23:387–393PubMedCrossRefGoogle Scholar
  20. 20.
    Lin GT, Tseng HF, Yang CH, Hou MF, Chuang LY, Tai HT, Tai MH, Cheng YH, Wen CH, Liu CS et al (2009) Combinational polymorphisms of seven CXCL12-related genes are protective against breast cancer in Taiwan. OMICS 13:165–172PubMedCrossRefGoogle Scholar
  21. 21.
    Kruszyna L, Lianeri M, Rubis B, Knula H, Rybczynska M, Grodecka-Gazdecka S, Jagodzinski PP (2010) CXCL12-3′ G801A polymorphism is not a risk factor for breast cancer. DNA Cell Biol 29:423–427PubMedCrossRefGoogle Scholar
  22. 22.
    Hassan S, Baccarelli A, Salvucci O, Basik M (2008) Plasma stromal cell-derived factor-1: host derived marker predictive of distant metastasis in breast cancer. Clin Cancer Res 14:446–454PubMedCrossRefGoogle Scholar
  23. 23.
    Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K (2002) A comprehensive review of genetic association studies. Genet Med 4:45–61PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2011

Authors and Affiliations

  • Weisheng Shen
    • 1
  • Xiangming Cao
    • 1
  • Lei Xi
    • 1
  • Lichun Deng
    • 1
  1. 1.Department of OncologyThe Affiliated Jiangyin Hospital of Southeast University Medical CollegeWuxiPeople’s Republic of China

Personalised recommendations